Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir

Ítems similars

• Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients
  per: Wood, Robin, et al.
  Publicat: (2004)
• In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV
  per: Hazen, Richard, et al.
  Publicat: (2007)
• Structural and Kinetic Analyses of the Protease from an Amprenavir-Resistant Human Immunodeficiency Virus Type 1 Mutant Rendered Resistant to Saquinavir and Resensitized to Amprenavir
  per: Markland, W., et al.
  Publicat: (2000)
• In Vitro Development of Resistance to Human Immunodeficiency Virus Protease Inhibitor GW640385
  per: Yates, P. J., et al.
  Publicat: (2006)
• Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing
  per: Sadler, Brian M., et al.
  Publicat: (2001)